SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Cadila gains on receives tentative approval from USFDA for Doxepin HcI tablets

27 Feb 2013 Evaluate

Cadila Healthcare is currently trading at Rs 767.20, up by 1.95 points or 0.25% from its previous closing of Rs 765.25 on the BSE.

The scrip opened at Rs 767.75 and has touched a high and low of Rs 770.00 and Rs 760.85 respectively. So far 1036 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 964.00 on 12-Sep-2012 and a 52 week low of Rs 683.50 on 16-Mar-2012.

Last one week high and low of the scrip stood at Rs 785.60 and Rs 758.05 respectively. The current market cap of the company is Rs 15708.31 crore.

The promoters holding in the company stood at 74.79% while Institutions and Non-Institutions held 16.32% and 8.89% respectively.

Zydus Cadila has received tentative approval from USFDA for Doxepin Hcl tablets in the strengths of 3 mg and 6 mg. The estimated sales in 2012 as per IMS for Doxepin Hcl, which falls in the neuropsychiatry segment was $15.5 million. It is scheduled to be launched in June 2020 upon patent expiry.

The group now has 77 approvals and has so far filed 172 ANDAs since the commencement of the filing process in FY 2003-04.

The flagship company of Zydus Cadila Group, focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.

Zydus Lifesciences Share Price

945.00 5.80 (0.62%)
17-Apr-2026 11:00 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1682.90
Dr. Reddys Lab 1222.60
Cipla 1236.70
Zydus Lifesciences 945.00
Lupin 2317.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×